# Valitor

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/valitor

- Industry: Biotechnology
- Headquarters: Berkeley, US
- Website: www.valitorbio.com
- Total disclosed funding: $17M
- Latest round: Series B (Dec 22, 2021)
- Investors on record: 5

## About

Valitor, Inc. is a biotechnology company focused on developing innovative ophthalmic therapies targeting vision-threatening diseases through its proprietary Multivalent Polymer technology platform.Founded in 2010 in Berkeley, US, Valitor, Inc. specializes in creating advanced therapies for ophthalmological conditions. The company has engaged in four total deals, with its most recent funding round being a Series B in December 2021, securing USD 8.45 mn led by Morningside Venture Partners. The company is led by CEO Steve Lo and co-founder Wesley Jackson, who have experience in the biotech sector. Valitor has not undergone significant pivots or changes and does not have known subsidiaries.Valitor, Inc. specializes in the development of innovative ophthalmic therapies, focusing primarily on addressing vision-threatening diseases through its proprietary Multivalent Polymer (MVP) technology platform. The company's lead product, VLTR-559, is an advanced, long-acting treatment for wet age-related macular degeneration (AMD), designed to improve patient outcomes by offering a twice-yearly dosing regimen. Valitor's MVP technology is engineered to enhance bioactive molecules' therapeutic durability, targeting ocular diseases while also addressing potential indications in oncology and joint diseases. The products are primarily marketed in North America and Europe, serving healthcare providers including ophthalmologists and hospitals.Valitor's revenue model centers on partnerships with pharmaceutical companies and healthcare institutions focused on ophthalmology. The company engages in B2B transactions, collaborating with other firms to facilitate the development and commercialization of its therapies. Revenue is generated through strategic collaborations involving shared development costs, clinical advancement milestones, and royalties on product sales upon market entry. The flagship product, VLTR-559, has potential revenue streams tied to clinical trials and market approval, though pricing plans have not been disclosed.In December 2021, Valitor, Inc. raised USD 8.45 mn in Series B funding to support its programs in ophthalmology and vision-threatening diseases. The company aims to expand its product offerings, although specific upcoming products and release dates have not been disclosed. Valitor plans to target new markets in Europe and North America for its therapies, utilizing the recent funding to enhance their market access and support the growth of its therapeutic offerings.

## Funding rounds

- Series B, Dec 22, 2021, $8.4M — Exsight ventures, Berkeley Catalyst Fund, Morningside, Pandect Bioventures, First Spark Ventures
- Series B, Dec 22, 2021, $8.4M — Exsight ventures, Berkeley Catalyst Fund, Morningside, Pandect Bioventures, First Spark Ventures

## Investors

- Exsight ventures (https://capitalatlas.ai/funds/exsight-ventures) — Series B
- Berkeley Catalyst Fund (https://capitalatlas.ai/funds/berkeley-catalyst-fund) — Series B
- Morningside (https://capitalatlas.ai/funds/morningside) — Series B
- Pandect Bioventures (https://capitalatlas.ai/funds/pandect-bioventures) — Series B
- First Spark Ventures (https://capitalatlas.ai/funds/first-spark-ventures) — Series B